JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

JNJ

190.6

-0.77%↓

ABT

126.77

+0.33%↑

MDT

93.77

-0.45%↓

VEEV

293.21

+0.68%↑

A

148.21

+0.39%↑

Search

SCYNEXIS Inc

Закрыт

0.77

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

0.76

Макс.

0.77

Ключевые показатели

By Trading Economics

Доход

-1.5M

-6.9M

Продажи

1.1M

1.4M

Рентабельность продаж

-504.765

Сотрудники

28

EBITDA

-4.3M

-9.6M

Рекомендации

By TipRanks

Рекомендации

Покупка

Прогноз на 12 месяцев

+419.48% upside

Рыночная статистика

By TradingEconomics

Рыночная капитализация

-2.1M

32M

Предыдущая цена открытия

0.77

Предыдущая цена закрытия

0.77

Техническая оценка

By Trading Central

Уверенность

Weak Bullish Evidence

SCYNEXIS Inc График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

24 окт. 2025 г., 18:41 UTC

Отчет

Procter & Gamble to Focus on Innovation, Not Discounts, to Attract Wary Shoppers - 2nd Update

24 окт. 2025 г., 18:31 UTC

Отчет

Correction to Procter & Gamble to Focus on Innovation

24 окт. 2025 г., 16:25 UTC

Главные движущие силы рынка

Obook Shares Rise, Company Secures New Money Transmitter Licenses

24 окт. 2025 г., 21:24 UTC

Обсуждения рынка

Global Forex and Fixed Income Roundup: Market Talk

24 окт. 2025 г., 21:24 UTC

Обсуждения рынка

Moody's Sees France With Increased Risk of Political Dysfunction -- Market Talk

24 окт. 2025 г., 21:07 UTC

Отчет

The Score: Netflix, Amazon.com, Six Flags and More Stocks That Defined the Week -- WSJ

24 окт. 2025 г., 20:58 UTC

Отчет

S&P 500 Climbs to New Record on Strong Earnings -- WSJ

24 окт. 2025 г., 20:50 UTC

Обсуждения рынка

Financial Services Roundup: Market Talk

24 окт. 2025 г., 20:40 UTC

Отчет

Intel Expects Chip Shortages on Better PC Demand. Here's Why AMD Is Winning Too. -- Barrons.com

24 окт. 2025 г., 20:24 UTC

Отчет

General Dyamics Stock Rises on Earnings. Aerospace Was a Standout. -- Barrons.com

24 окт. 2025 г., 20:23 UTC

Отчет

General Dyamics Stock Rises on Earnings. Aerospace Was a Standout. -- Barrons.com

24 окт. 2025 г., 20:13 UTC

Отчет

These Stocks Moved the Most Today: Intel, AMD, Ford, Deckers, Newmont, Nextracker, Booz Allen, Coinbase, and More -- Barrons.com

24 окт. 2025 г., 20:07 UTC

Обсуждения рынка

Different-Cell Imputation Rose Proportionally in September CPI -- Market Talk

24 окт. 2025 г., 19:40 UTC

Обсуждения рынка

Treasury Yields Mixed, Dollar Stronger Ahead of Fed Week -- Market Talk

24 окт. 2025 г., 19:35 UTC

Обсуждения рынка

Oil Rally on U.S. Russia Sanctions Loses Steam -- Market Talk

24 окт. 2025 г., 19:33 UTC

Отчет

IBM and Google Are Also Making Moves in Quantum. Don't Count Out the Bigger Players. -- Barrons.com

24 окт. 2025 г., 19:29 UTC

Обсуждения рынка

U.S. Natural Gas Ends Week Higher on Weather Outlook -- Market Talk

24 окт. 2025 г., 18:52 UTC

Отчет

Correction to GM Stock Soars to Record High. Earnings Were So Good, They Helped Ford. -- Barrons.com

24 окт. 2025 г., 18:41 UTC

Отчет

GM Stock Soars to Record High. Earnings Were So Good, They Helped Ford. -- Barrons.com

24 окт. 2025 г., 18:03 UTC

Отчет

Beyond Meat Stock Is on a Wild Ride. Why a Meme Rally Looks Undercooked. -- Barrons.com

24 окт. 2025 г., 18:02 UTC

Отчет

Progressive Stock Got Hit After Earnings. It's Time to Buy One of America's Great Companies. -- Barrons.com

24 окт. 2025 г., 18:00 UTC

Обсуждения рынка

U.S. Oil Rig Count Rises By Two to 420 -- Market Talk

24 окт. 2025 г., 16:57 UTC

Отчет

Ford Stock Has Quadrupled Tesla's Gains. What's Behind Its Meteoric Rise. -- Barrons.com

24 окт. 2025 г., 16:54 UTC

Обсуждения рынка

End to Canada-U.S. Trade Talks Not Seen Shifting Nearterm Outlook -- Market Talk

24 окт. 2025 г., 16:44 UTC

Обсуждения рынка
Отчет

Amazon Retail Looks Strong as Consumer Sentiment Improves -- Market Talk

24 окт. 2025 г., 16:39 UTC

Обсуждения рынка
Отчет

Amazon Sentiment Around AWS Seen as Improving in 3Q -- Market Talk

24 окт. 2025 г., 16:33 UTC

Отчет

These Stocks Are Moving the Most Today: Intel, AMD, Ford, Deckers, Newmont, Nextracker, Booz Allen, Coinbase, and More -- Barrons.com

24 окт. 2025 г., 16:23 UTC

Отчет

These Stocks Are Moving the Most Today: Intel, AMD, Ford, Deckers, Newmont, Nextracker, Booz Allen, Coinbase, and More -- Barrons.com

24 окт. 2025 г., 16:20 UTC

Обсуждения рынка

Financial Services Roundup: Market Talk

24 окт. 2025 г., 16:07 UTC

Отчет

Ford Stock Has Quadrupled Tesla's Gains. What's Behind Its Meteoric Rise. -- Barrons.com

Сравнение c конкурентами

Изменение цены

SCYNEXIS Inc Прогноз

Целевая цена

By TipRanks

419.48% рост

Прогноз на 12 месяцев

Средняя 4 USD  419.48%

Максимум 4 USD

Минимум 4 USD

Основано на мнении 1 аналитиков Wall Street, спрогнозировавших целевые цены для SCYNEXIS Inc на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Покупка

1 ratings

1

Покупка

0

Удержание

0

Продажа

Техническая оценка

By Trading Central

0.9307 / 0.9907Поддержка и Сопротивление

Краткосрочная

Weak Bullish Evidence

Среднесрочная

Weak Bearish Evidence

Долгосрочная

No Evidence

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании SCYNEXIS Inc

SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It also develops SCY-247 to treat systemic fungal diseases. The company has licensing and collaboration agreements with GlaxoSmithKline Intellectual Property (No. 3) Limited, Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC for the development, manufacture, and commercialization of ibrexafungerp. SCYNEXIS, Inc. was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. The company was incorporated in 1999 and is headquartered in Jersey City, New Jersey.
help-icon Live chat